Toxicity and dose-response studies of 1-α hydroxyvitamin D2 in LH-β-tag transgenic mice

Conclusions In the LHβ-Tag mouse, 1α-OH-D 2 inhibits retinoblastoma with no significant increase in mortality in lower doses (0.1–0.3 μg). 1α-OH-D 2 has approval by the Food and Drug Administration as an investigative drug for cancer treatment, and has shown efficacy with low toxicity in adult cancer trials. 1α-OH-D 2 meets the criteria for human clinical trials.